I.V. is used for delivery of medication and fluid, blood transfusions, and others in patients. It is used in patients for fluid replacement, to maintain electrolyte balance, or in patients with physical debility, and unconscious patients. I.V. dressing offers quick fixation dressing to secure I.V. Cannula, intramuscular catheters, and other percutaneous devices to the skin. I.V. dressing are transparent or translucent dressing made of adhesive material, and polyurethane collated films, which prevents bacterial infection at the injection site and also prevents moisture buildup to protect against dust and germs

Request a sample copy of this report:- https://www.coherentmarketinsights.com/insight/request-sample/3182

Rising incidences of infections such as central line associated bloodstream infection (CLABSI), catheter-related bloodstream infection (CRBSI), and other infections are expected to boost growth of the I.V. dressing market over the forecast period. For instance, according to the data published in National Healthcare Safety Network Bloodstream Infection Surveillance in March 2018, around 30,000 CLABSI cases are reported every year in the U.S. CLABSI can prolong the hospital stay, which can increase the cost burden on patients and also may lead to mortality.

Furthermore, according to the International Society for Infectious Diseases, March 2018, around 250,000 cases of blood stream are reported every year in the U.S. among these, around 80,000 are catheter-related bloodstream infection (CRBSI), which occurs in intensive care units.

North America accounted for the largest market share in 2018, owing to launches and approvals of new I.V. dressing products in the region. For instance, in January 2016, Entrotech life sciences, a U.S.-based company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ChloraDerm dressing, which protects against multi-drug-resistant organisms and other catheter-related bloodstream infections. Moreover, in September 2016, Becton, Dickinson and Company and Vancive Medical Technologies entered into a collaboration to launch a line of ChloraShield I.V. dressings developed for vascular access dressing and enhancing patient care. Therefore, these factors are expected to boost growth of the global I.V. dressing market over the forecast period.

Key players operating in the global I.V. dressing market include Medline Industries, 3M, Paul Hartmann AG, Deroyal, Tytex Inc., Reliamed, Acelity, BSN Medical, CareFusion, Lohmann & Rauscher, Smith & Nephew, Shandong Dermcosy Medical Co.,Ltd., Talent Health Care, Datt Mediproducts Private Limited, and Others.
Moreover, key players in the market are focused on developing new products, in order to enhance their market share. For instance, in 2015, 3M launched Tegaderm CHG Chlorhexidine Gluconate I.V. port dressing for the patients with port devices under the skin, who are connected to catheter for central venous infusion.

Get the main link:- https://www.coherentmarketinsights.com/ongoing-insight/iv-dressing-market-3182

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/